Vinyl Health

An AI-powered personal health assistant that records visits, organizes records, and clarifies care.

Cover Block

Publicly reported

Field	Value
Name	Vinyl Health
Tagline	An AI-powered personal health assistant that records visits, organizes records, and clarifies care [Vinyl Health, retrieved 2026]
Headquarters	Marlton, NJ, United States [Crunchbase, retrieved 2026]
Founded	2024 [Crunchbase, retrieved 2026]
Stage	Seed [Crunchbase, retrieved 2026]
Business Model	B2C
Industry	Healthtech
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+): Kaitlan Baston, Eric Uhe, Nilesh Bhandari [Morningstar, October 2026]
Funding Label	Seed
Total Disclosed	~$2,000,000 [Business Wire, October 2026]

Summary and Signal

PUBLIC Vinyl Health is building a consumer health assistant that records doctor visits, organizes records, and translates care information into clearer next steps, a pitch that has become more investable now that the company has both public app distribution and a disclosed seed round [Vinyl Health, retrieved 2026] [Apple App Store, retrieved 2026] [Google Play, retrieved 2026] [Business Wire, October 2026]. Founded in 2024 in New Jersey, the company is still early, but its public launch appears to coincide with a $2 million seed financing led by HealthX Ventures announced in October 2026, giving investors a concrete funding milestone rather than a concept-stage story alone [Crunchbase, retrieved 2026] [Business Wire, October 2026] [Citybiz, October 2026].

The product thesis is straightforward: Vinyl sits with the patient rather than the provider workflow, using a mobile app to capture visits, maintain a personal health record, and help users share updates with family, caregivers, and clinicians [Vinyl Health, retrieved 2026] [Preqin, retrieved 2026]. That positioning matters because the differentiation, at least in public materials, is less about a novel model layer and more about patient-controlled context, plain-language interpretation, and care-circle coordination in a fragmented healthcare system [Vinyl Health, retrieved 2026] [Business Wire, October 2026].

The founding story also gives the company more credibility than a typical consumer health app launch. Kaitlan Baston, identified publicly as founder and CEO, previously served as New Jersey Commissioner of Health and interim President and CEO of University Hospital in Newark, and earlier built the Cooper Center for Healing, an integrated pain, addiction, and behavioral health center [Business Wire, October 2026] [NJHCQI, retrieved 2026] [ASTHO, retrieved 2026]. Publicly surfaced team references also name Eric Uhe as CTO and Nilesh Bhandari as CPO, though those role details rely on lighter corroboration than Baston's background [RocketReach, retrieved 2026] [Fundup AI, retrieved 2026].

On the financing side, the cleanest public signal is the October 2026 seed announcement, while a June 2026 Form D showing $1 million sold of a $2,499,998 offering suggests the round may have been assembled over time rather than closed in a single public event [Form D, June 2026] [Business Wire, October 2026]. The company is described as B2C, the app is presented as free to download, and Vinyl states on its website that its model does not depend on selling users' health data, but monetization beyond that remains to be proven in public evidence [Vinyl Health, retrieved 2026].

Over the next 12 to 18 months, the main questions are whether Vinyl can convert public launch into sustained consumer usage, whether any provider or employer distribution motion emerges from its multi-stakeholder positioning, and whether a five-person team can execute across compliance, product iteration, and go-to-market at the same time [PitchBook, retrieved 2026] [RocketReach, retrieved 2026] [Vinyl Health, retrieved 2026]. The company has a credible founder-market fit and a legible initial product, but the public record is still light on customer proof, retention, and commercial partnerships, so the near-term watch items are traction quality and distribution efficiency rather than category formation risk [Business Wire, October 2026] [Crunchbase, retrieved 2026].

No independent source found -- Core company, product, and business model claims in this section rely materially on company materials and announcement coverage, with some independent corroboration from app store listings, Form D, and company databases.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	B2C
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	Seed, total disclosed about $2,000,000

Company Overview

Publicly reported Vinyl Health appears to be taking a consumer-first approach to a familiar healthcare problem, the gap between what happens in a visit and what patients can actually retain, organize, and act on afterward. The company describes itself as a personal health assistant that records visits, turns them into notes and next steps, and keeps health records in one place for sharing with a support network [Vinyl Health, retrieved 2026]. Crunchbase lists Vinyl Health as a Marlton, New Jersey-based company founded in 2024 [Crunchbase, retrieved 2026].

The public timeline is still short, but the sequence is clear enough. Crunchbase dates the company to 2024 [Crunchbase, retrieved 2026], while the company website shows a live consumer-facing product and partner messaging for individuals, caregivers, providers and health systems, employers, and care navigators [Vinyl Health, retrieved 2026]. By October 2026, Vinyl Health had announced a $2 million seed round led by HealthX Ventures, a financing that coincided with the broader public launch of its app and gave the company its first widely reported institutional milestone [Crunchbase, retrieved 2026].

What is less clear from public records is the legal architecture behind the operating brand. The available public materials establish the headquarters, founding year, product framing, and seed financing, but they do not add much detail on corporate structure beyond the company name carried in startup databases and the website brand presentation [Crunchbase, retrieved 2026] [Vinyl Health, retrieved 2026]. That leaves Vinyl Health in an early category where the core question is not whether it exists, but how quickly it can convert a credible public launch into durable user adoption.

One source, partially checked -- Based primarily on Crunchbase and the company website, with partial corroboration across those two public sources.

The Product and the Stack

MIXED Product and Technology

The product is easiest to understand as a consumer health companion built around one narrow but meaningful moment: the doctor visit. Vinyl Health describes its app as a personal health assistant that records visits, turns them into notes and next steps, keeps health records in one place, and helps a user’s support network stay informed [Vinyl Health, retrieved 2026]. Public app store listings corroborate that the product is distributed through both Google Play and Apple’s App Store [Vinyl Health - Apps on Google Play, retrieved 2026] [Vinyl Health App - App Store, retrieved 2026].

The feature set described across the company website and funding coverage stays consistent on a few core workflows. Vinyl says users can capture visits and voice notes, organize care information, queue questions for future appointments, and share updates with clinicians, caregivers, and family members [Vinyl Health, retrieved 2026] [Morningstar, October 2026] [Citybiz, October 2026]. A Preqin profile adds that the platform enables users to record how they are feeling, confirm medication regimens, and track questions for healthcare providers [Preqin, retrieved 2026]. The company also states that the app is free to download and HIPAA-aligned, although that claim remains company-sourced rather than independently validated [Vinyl Health, retrieved 2026].

On the technology side, the public description points to ambient AI as the interface layer rather than a deeper disclosed infrastructure story. Coverage of the October 2026 seed round says the app uses AI to help patients record, understand, and share care information, and the website frames the output as clearer notes and next steps rather than diagnostic or clinical decision support [Morningstar, October 2026] [Dealroom News, October 2026] [Vinyl Health, retrieved 2026]. That distinction matters: based on the public record, Vinyl appears positioned as a patient comprehension and coordination tool, not as a provider workflow system or regulated medical device. The website does signal adjacent surfaces for providers, employers, care navigators, and health systems, but the retrieved public materials do not establish how far those offerings extend beyond the core consumer experience [Vinyl Health, retrieved 2026].

No independent source found -- Core product availability is confirmed by Apple App Store and Google Play, but most feature and technical capability claims rely on company materials and reprinted company announcements.

The Market They Are Entering

Publicly reported The market matters now because Vinyl Health sits at the intersection of two live pressures in U.S. healthcare: patients are carrying more of the coordination burden themselves, and generative AI has made visit capture and plain-language summarization newly feasible at the consumer edge [Signal and Symptoms Podcast, October 2026] [Healthcare podcast, May 2026].

The evidence base here is thinner than it would be for a more mature category, and that shapes the analysis. No named third-party market report for Vinyl’s exact segment, a consumer personal health assistant that records visits, organizes records, and clarifies care, was provided in the research set. The cleaner way to frame TAM is therefore through adjacent, analogous markets rather than a precise dollar claim: patient engagement software, digital health record access, care navigation, and AI clinical documentation each touch parts of the workflow Vinyl is trying to collapse into one user-controlled product [Vinyl Health, retrieved 2026] [Morningstar, October 2026].

That matters because the company is not entering a single settled software budget line. Its public materials present surfaces for individuals, caregivers, providers, employers, and care navigators, which suggests a market definition broader than a standalone consumer app and closer to a patient experience layer that could travel across several healthcare distribution channels if adoption emerges [Vinyl Health, retrieved 2026]. At this stage, though, the public record supports product ambition more clearly than market capture. No public customer counts, payer contracts, health-system deployments, or revenue figures were cited in the source set [Morningstar, October 2026] [Dealroom News, October 2026].

Analogous market lenses

Publicly reported Because no directly sourced TAM, SAM, or SOM figures were captured for Vinyl’s exact category, the most disciplined approach is to show the adjacent lenses the company appears to map onto.

Market lens	Relevance to Vinyl	Evidence in source set
Consumer health record and visit management	Core use case, users record visits, keep records in one place, and track next steps	[Vinyl Health, retrieved 2026]
Caregiver coordination tools	Vinyl explicitly markets to caregivers and support networks	[Vinyl Health, retrieved 2026]
Patient engagement layer for providers and health systems	Vinyl presents a provider and health-system surface focused on patient experience	[Vinyl Health, retrieved 2026]
Employer and care navigator support tools	Vinyl also frames the product for employers and care navigators	[Vinyl Health, retrieved 2026]

The table underscores both the appeal and the ambiguity. Vinyl can plausibly attach to several healthcare software budgets, but the public evidence does not yet show which entry point is converting first or whether the primary motion is B2C acquisition, institutional distribution, or a hybrid model [Vinyl Health, retrieved 2026] [Citybiz, October 2026].

Demand drivers and adjacent markets

Publicly reported Demand appears to be driven less by a new reimbursement code and more by a persistent coordination problem. Vinyl’s pitch, repeated across its website and funding coverage, is that patients leave visits with fragmented notes, unclear next steps, and family members who are not fully informed, especially when care spans multiple providers [Vinyl Health, retrieved 2026] [Morningstar, October 2026] [Citybiz, October 2026]. If that problem is acute enough, a recording-and-translation tool has a clear consumer logic even before it has an enterprise one.

Two adjacent markets matter most. The first is ambient documentation, where AI systems capture spoken interactions and convert them into usable notes. The second is care navigation and patient engagement, where the goal is not documentation alone but helping patients act on what happened and share it with caregivers or clinicians [Healthcare podcast, May 2026] [Vinyl Health, retrieved 2026]. Vinyl’s differentiation, based on the public materials, is that it tries to push ambient capture downstream to the patient rather than anchoring the workflow inside the clinician’s EHR environment [Morningstar, October 2026] [Vinyl Health, retrieved 2026].

That positioning could widen the addressable user base, but it also changes the go-to-market challenge. Consumer health products often need sustained engagement, trust on data handling, and a convincing reason to become part of a user’s routine, while enterprise health products need procurement, integration, and compliance proof. Vinyl’s public materials suggest it may be testing demand across both domains at once [Vinyl Health, retrieved 2026].

Regulatory and macro forces

Publicly reported The regulatory backdrop is supportive in concept, but still exacting in execution. Vinyl describes the app as HIPAA-aligned and emphasizes that its business model does not depend on selling users’ health data, both of which speak directly to a market where privacy concerns can suppress adoption if the product narrative is not credible [Vinyl Health, retrieved 2026]. In healthcare AI, trust is part of distribution.

Macro conditions also help explain timing. Public discussion from Baston’s 2026 podcast appearances centered on AI governance, patient empowerment, fragmentation of care, and the need to translate clinical information into more usable guidance, themes that fit a post-LLM environment where summarization and natural-language interfaces have become more practical but are still under scrutiny [Healthcare podcast, May 2026] [TechTalk Healthcare, April 2026] [Signal and Symptoms Podcast, October 2026]. That does not prove category breakout, but it does suggest the company is being launched into a window where the problem statement is legible to both consumers and healthcare institutions.

The harder regulatory question is narrower and product-specific: when visit recording is patient-controlled, consent norms, state-by-state recording rules, and provider comfort can affect usage even if the software itself is easy to adopt. The source set does not establish how Vinyl handles those edge cases in practice, so that remains a live diligence item rather than a documented strength [Vinyl Health, retrieved 2026].

No independent source found -- This section relies primarily on company materials and publisher coverage of the company, with no named third-party market sizing report in the source set and no independently verified TAM, SAM, or SOM figures.

The Competitive Field

MIXED Vinyl Health is positioning itself less against a single named startup than against a stack of existing patient workflows, health-system portals, and clinical note tools that already mediate how people remember and act on care instructions [Vinyl Health, retrieved 2026] [Business Wire, October 2026].

The competitive map is easiest to read in segments rather than logos. On one side are incumbent patient access layers, chiefly provider-tethered portals and record systems, which already store visit summaries, lab results, medication lists, and messages but are usually organized around the health system rather than the patient’s full cross-provider history [Vinyl Health, retrieved 2026]. On another side are challenger products in ambient documentation and AI summarization, a category Vinyl explicitly touches through visit recording and note generation, although the public source set here does not name direct peers by company [Business Wire, October 2026] [Citybiz, October 2026]. The adjacent substitutes are lower-tech and often more entrenched than software investors like to admit: phone recordings, paper notebooks, caregiver group texts, and ad hoc document folders remain the default care-coordination layer for many households dealing with fragmented care [Vinyl Health, retrieved 2026] [TechTalk Healthcare, April 2026].

Vinyl’s clearest edge today is not scale or capital, because the company has only a disclosed $2 million seed round and roughly five employees according to public databases [Business Wire, October 2026] [PitchBook, retrieved 2026] [RocketReach, retrieved 2026]. The edge is instead product framing and founder-market fit. Public materials consistently describe the app as patient-controlled, cross-context, and designed to turn visits into clear notes and next steps, while founder Kaitlan Baston brings unusually relevant healthcare operating credibility from roles that included New Jersey Commissioner of Health and interim president and CEO of University Hospital in Newark [Vinyl Health, retrieved 2026] [Morningstar, October 2026] [NJHCQI, retrieved 2026]. That helps with trust and possibly with future health-system conversations, but it is also a perishable advantage if larger platforms add consumer-facing visit summarization faster than Vinyl can build retention and proprietary usage data.

The exposure is fairly specific. Incumbent portals and record vendors already own authenticated patient relationships at the point where medical data originates, and they control a distribution surface Vinyl does not yet own, namely the default digital destination patients see after an appointment [Vinyl Health, retrieved 2026]. At the same time, specialist ambient AI vendors aimed at clinicians may have a simpler wedge because providers can mandate workflow adoption inside the visit, whereas a consumer app still has to earn repeated use appointment by appointment [Business Wire, October 2026]. Vinyl may have a more patient-aligned product thesis than those categories, but public evidence does not yet show named enterprise partners, payer channels, or health-system deployments that would offset that structural distribution gap [Crunchbase, retrieved 2026] [Dealroom News, October 2026].

The most plausible 18-month scenario is that the category bifurcates. The likely winner, if patient-controlled records and post-visit comprehension become a recognized care-navigation need, is Epic MyChart as the incumbent reference point, because it already sits inside the provider relationship and can absorb selected AI summarization features through existing portal traffic; that is an inference from channel control rather than a reported product roadmap [Vinyl Health, retrieved 2026] (estimated). The likely loser, if consumers prove unwilling to maintain a separate health app without direct provider distribution, is any standalone patient assistant that lacks embedded partnerships, and Vinyl would fit that risk profile based on the current public record [Crunchbase, retrieved 2026] [Business Wire, October 2026]. The counter-scenario is that Vinyl’s consumer-first design resonates with caregivers and medically complex households in a way portals do not, but public evidence is still too early to call that a demonstrated competitive breakout.

Thinly sourced -- Section relies on public company materials and funding coverage, with competitive inferences drawn from product positioning and distribution structure rather than named, source-confirmed direct competitors.

Opportunity

PUBLIC The prize here is not a better note-taking app, it is a patient-controlled coordination layer that sits between fragmented healthcare encounters and the people who have to act on them, a position that could become valuable if consumer trust, provider usefulness, and care-network sharing compound together [Vinyl Health, retrieved 2026] [Morningstar, October 2026].

The headline opportunity is fairly specific. If Vinyl Health executes, it could become the consumer system of record for day-to-day care navigation: the place where a patient records visits, consolidates records, translates clinical language into plain English, and then shares the useful parts with family, caregivers, and clinicians [Vinyl Health, retrieved 2026] [Morningstar, October 2026] [Citybiz, October 2026]. That outcome is reachable, rather than merely aspirational, because the company has already shipped a public mobile product on both major app stores and framed the product around a real operational gap in healthcare, namely that visit details, next steps, medication context, and family coordination are often scattered across portals, paper instructions, and memory [Apple App Store, retrieved 2026] [Google Play, retrieved 2026] [Vinyl Health, retrieved 2026]. The seed round led by HealthX Ventures does not prove product-market fit, but it does suggest enough outside conviction to fund an initial launch and distribution test at the moment of broader public availability [Business Wire, October 2026] [Crunchbase, retrieved 2026].

The upside paths are still narrow, but they are legible from the current product surface.

Scenario	What happens	Catalyst	Why it's plausible
Consumer care companion	Vinyl becomes a repeat-use app for patients and caregivers who need to capture visits, track questions, and keep a support circle aligned across multiple encounters	Broad consumer adoption following public launch on iOS and Android, especially if care-circle sharing becomes habitual [Apple App Store, retrieved 2026] [Google Play, retrieved 2026]	The current product already centers on recording visits, organizing records, and keeping family or caregivers informed, which gives it a use case that extends beyond a single appointment [Vinyl Health, retrieved 2026] [Preqin, retrieved 2026]
Employer and navigator channel	Vinyl sells its coordination layer through employers or care navigators as a member-engagement tool for workers and dependents managing complex care	Early channel partnerships with employers, navigators, or care-coordination programs that need better patient follow-through [Vinyl Health, retrieved 2026]	The website explicitly presents product surfaces for employers and care navigators, indicating the company is at least designing for non-consumer distribution paths from the outset [Vinyl Health, retrieved 2026]
Provider-adjacent engagement layer	Vinyl becomes a front-end patient experience tool used alongside health systems, helping patients leave visits with clearer instructions and a shareable summary	A health-system partnership or provider workflow integration that treats Vinyl as an engagement layer rather than a replacement record system [Vinyl Health, retrieved 2026] [Morningstar, October 2026]	The company already positions itself for providers and health systems and describes a workflow where users can organize updates and share them back into their care network, which is directionally aligned with provider adoption if trust and compliance hold [Vinyl Health, retrieved 2026] [Citybiz, October 2026]

The compounding mechanism would come from depth of engagement, not from a one-time download. A patient who uses the app to record one visit may return because medications, follow-up questions, and new records accumulate over time; that patient may then pull in a caregiver or family member, which raises switching costs because the value shifts from personal recall to shared coordination [Vinyl Health, retrieved 2026] [Preqin, retrieved 2026]. If provider or employer channels develop later, those networks can add lower-cost distribution on top of consumer utility already proven in the field. The early signs of that flywheel are modest but visible in the product design itself: Vinyl emphasizes record consolidation, visit capture, plain-language interpretation, care-circle communication, and access across mobile and web, all of which support repeat use rather than a single episodic task [Vinyl Health, retrieved 2026] [Google Play, retrieved 2026] [Apple App Store, retrieved 2026].

The size of the win is best thought of in scenario terms because no credible public market-sizing data was provided in the source set. In the strongest case, Vinyl matures into a scaled patient-engagement platform with multiple channels, consumer retention, and enterprise distribution, at which point strategic value could resemble the premium paid for sticky healthcare workflow or navigation assets rather than a simple wellness app multiple (scenario, not a forecast). The public evidence is not yet strong enough to anchor a precise valuation range, but the combination of a physician-founder with state-level health leadership experience, a live cross-platform product, and an initial institutional seed round makes a meaningful outcome conceivable if the company can prove retention and channel conversion over the next few years [NJHCQI, retrieved 2026] [Morningstar, October 2026] [Apple App Store, retrieved 2026] [Google Play, retrieved 2026].

No independent source found -- This section relies materially on company materials and republished launch coverage for product scope and opportunity framing, with partial corroboration from app store listings and Crunchbase for funding context.

Sources